24/7 Market News Snapshot 06 February, 2025 – Equillium, Inc. Common Stock (NASDAQ:EQ)

February 6, 2025

DENVER, Colo., 06 February, 2025 (247marketnews.com) – (NASDAQ:EQ) are discussed in this article.
Equillium, Inc. is witnessing a notable bullish trend in pre-market trading, with shares priced at $0.763, reflecting a gain of 7.48% from the previous session’s close of $0.710. Trading volume has surged to 8.97 million shares, indicating increased investor enthusiasm and strong market sentiment, likely influenced by recent developments surrounding the company’s lead investigational therapy, itolizumab.

In a significant advancement, Equillium recently announced positive topline results from its Phase 2 study of itolizumab, targeting moderate to severe ulcerative colitis (UC). This study, co-sponsored with Biocon Limited, demonstrated itolizumab’s potential to provide substantial clinical benefits for patients who typically face limited treatment options. Conducted as a double-blinded, placebo-controlled trial, the study assessed 90 biologic-naïve patients who were randomized to receive either itolizumab, a placebo, or the standard treatment adalimumab over an initial 12-week period.

Notably, 23% of patients treated with itolizumab achieved clinical remission, highlighting its efficacy in a cohort characterized by high baseline severity. Additionally, a clinical response rate of 63.3% among itolizumab recipients was reported, surpassing results from both the placebo and adalimumab groups. Dr. Stephen Connelly, Chief Scientific Officer at Equillium, expressed excitement about these findings, reinforcing their commitment to advancing itolizumab in the market.

Dr. Brian Feagan, an authority in gastroenterology, emphasized the promising nature of the study’s results when compared to existing biologic therapies. With its unique approach targeting the CD6-ALCAM signaling pathway, itolizumab aims to enhance treatment outcomes while minimizing associated safety risks. Looking ahead, Equillium anticipates presenting more data at a future scientific conference in 2025, which could further illuminate the therapeutic potential of itolizumab across various inflammatory diseases.

Related news for (EQ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.